Related Experiment Video
Updated: Jun 7, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Colorectal gastrointestinal stromal tumor
1Department of Surgery, Unit of Coloproctology, Via Borea, 56, 18038 Sanremo, Italy. a.amato@asl1.liguria.it
Techniques in Coloproctology
|October 23, 2010
Summary
Gastrointestinal stromal tumors (GISTs) are common digestive tract neoplasms often driven by KIT or PDGFRα mutations. Targeted therapies like imatinib mesylate offer promising treatment options, especially for advanced or high-risk GISTs.
Area of Science:
- Gastroenterology
- Oncology
- Molecular Biology
Background:
- Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm of the digestive tract, linked to interstitial cells of Cajal.
- GISTs typically exhibit KIT proto-oncogene mutations (up to 90%), with exon 11 being most frequent, or PDGFRα mutations in a third of cases.
- Colorectal GISTs comprise 5-10% of cases, often in the rectum, with risk assessment relying on tumor size and mitotic rate.
Purpose of the Study:
- To review the characteristics, risk assessment, and treatment strategies for colorectal GISTs.
- To highlight the evolving role of targeted molecular therapy in managing GISTs.
Main Methods:
- Literature review of GIST epidemiology, pathology, and treatment modalities.
- Analysis of surgical and medical therapeutic strategies, including targeted therapies.
Main Results:
- Surgery (segmental colectomy or local excision) is the primary treatment for resectable colorectal GISTs, though not always curative for high-risk cases.
- Imatinib mesylate has demonstrated efficacy in metastatic and unresectable GISTs.
- Adjuvant and neoadjuvant imatinib show promise for improving surgical outcomes and enabling less extensive resections.
Conclusions:
- While surgery is foundational, targeted therapies like imatinib are crucial for managing advanced or high-risk GISTs.
- Neoadjuvant and adjuvant imatinib represent promising strategies to enhance surgical management and patient outcomes in GIST treatment.